Summary
Mometasone Furoate has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Asthma would be drug repurposing rather than first-in-human development. This does not mean it is approved for Asthma. ClinicalTrials.gov lists 8 registered trials linking Mometasone Furoate to Asthma: 8 have completed. The most advanced is Phase 4 (NCT00711165). The largest enrolment is 2283 participants (NCT00941798). Registration activity spans 2005 to 2024. The literature layer holds 11 publications for this pair: 1 Cochrane review, 4 meta-analyses, 1 systematic review and 5 clinical trial publications. Publication years run from 2009 to 2025. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.
The RepurpOS disease-intelligence file for Asthma ranks 642 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: 26% of childhood-onset asthma in clinical remission by adulthood; <20% adult-onset achieves sustained remission; 65% long-term remission in mild-moderate vs 16% in severe.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 77.5 (trials 27.5, literature 30.0, tier 15, approved bonus 5.0) |
| Registered trials | 8 total: 0 recruiting, 0 active / not yet recruiting, 8 completed, 0 other |
| Linked publications | 11 (5 clinical trial publications, 4 meta-analyses, 1 Cochrane review, 1 systematic review) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | Open Targets, ChEMBL |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT00711165 | Mometasone and Markers of Airway Inflammation 2005 | completed | Phase 4 | 12 |
| NCT00381485 | Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04431AM2)(COMPLETED) 2006 | completed | Phase 3 | 834 |
| NCT00941798 | Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma 2009 | completed | Phase 2 | 2,283 |
| NCT00746330 | Single Dose Study of the Effect of Formoterol Fumarate in Combination With Mometasone Furoate Inhaled Via a Pressurized Metered Dose Inhaler (pMDI) in Children Aged 5-11 Years Old With Persistent Asthma 2008 | completed | Phase 2 | 32 |
| NCT01555151 | Safety and Efficacy of Mometasone Furoate Delivered Via Concept1 Device or Twisthaler® Device in Adult and Adolescent Patients With Persistent Asthma 2012 | completed | Phase 2 | 739 |
| NCT01061333 | Early Airway Response to Allergen in Asthmatics (MK-0000-176) 2010 | completed | Phase 1 | 16 |
| NCT02415179 | Effect of Inhaled Mometasone/Formoterol Versus Inhaled Fluticasone/Salmeterol in Asthma Patients 2015 | completed | Not applicable | 52 |
| NCT06573164 | Allergic Rhinitis With/Without Asthma: Pre- and Post-Qipian Analysis 2024 | completed | Not applicable | 60 |
Published literature
- Clinical trial publication A Novel Metered Dose Inhaler Formulation of Triple-Drug Fixed-Dose Combination of Vilanterol, Glycopyrronium, and Fluticasone Furoate: A Phase III, Randomized, Multicenter Trial to Evaluate the Efficacy and Safety in Indian Patients With Uncontrolled AsthmaPatel C, Sahoo D, Sheth V et al. · Clinical therapeutics · 2025 · PMID 41168047
- Clinical trial publication Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trialDe Corso E, Canonica GW, Heffler E et al. · The Lancet. Respiratory medicine · 2025 · PMID 41033334
- Clinical trial publication Efficacy and safety of novel fixed dose combination of vilanterol, glycopyrronium, and fluticasone furoate dry powder inhaler: A phase 3, randomized, non-inferiority trial compared with fixed dose combination of indacaterol, glycopyrronium, and mometasone furoate dry powder inhaler in Indian asthma patientsPatel C, Sheth V, Koppula R et al. · Respiratory medicine · 2025 · PMID 40759266
- Clinical trial publication Efficacy, Safety, and Systemic Exposure of Once-Daily Indacaterol Acetate in Pediatric Asthma: A Randomized, Double-Blind, Controlled Dose-Finding StudySekerel BE, Nell H, Laki I et al. · Clinical drug investigation · 2023 · PMID 37682405
- Clinical trial publication Efficacy of mometasone/indacaterol/glycopyrronium in patients with inadequately controlled asthma with respect to baseline eosinophil count: Post hoc analysis of IRIDIUM studyKostikas K, Maspero JF, Chapman KR et al. · Respiratory medicine · 2023 · PMID 37392789
- Meta-analysis Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler(®) Device in Patients with AsthmaBartels C, Jain M, Yu J et al. · European journal of drug metabolism and pharmacokinetics · 2021 · PMID 34024035
- Systematic review Measures to reduce maintenance therapy with oral corticosteroid in adults with severe asthmaNguyen VQ, Ulrik CS · Allergy and asthma proceedings · 2016 · PMID 27931289
- Cochrane review Inhaled corticosteroids in children with persistent asthma: effects on growthZhang L, Prietsch SO, Ducharme FM · The Cochrane database of systematic reviews · 2014 · PMID 25030198
- Meta-analysis Appraisal of lens opacity with mometasone furoate/formoterol fumarate combination in patients with COPD or asthmaMaspero J, Cherrez I, Doherty DE et al. · Respiratory medicine · 2014 · PMID 25044280
- Meta-analysis Comparison of the efficacy and safety of mometasone furoate to other inhaled steroids for asthma: a meta-analysisYang D, Wang J, Bunjhoo H et al. · Asian Pacific journal of allergy and immunology · 2013 · PMID 23517391
- Meta-analysis Frequency of dosing and comparative doses of mometasone furoate: a meta-analysisHart K, Weatherall M, Shirtcliffe P et al. · Respirology (Carlton, Vic.) · 2009 · PMID 19818054
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Mometasone Furoate approved for Asthma?
Mometasone Furoate has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Asthma would be drug repurposing rather than first-in-human development. This does not mean it is approved for Asthma. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Mometasone Furoate in clinical trials for Asthma?
ClinicalTrials.gov lists 8 registered trials linking Mometasone Furoate to Asthma: 8 have completed. The most advanced is Phase 4 (NCT00711165). The largest enrolment is 2283 participants (NCT00941798). Registration activity spans 2005 to 2024.
What does the evidence show for Mometasone Furoate in Asthma?
Mometasone Furoate has both completed registered trials and synthesis-level publications linked to Asthma. That is the strongest profile in this database, but the summaries here do not extract effect sizes, so read the linked reviews for direction and magnitude of benefit. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.